Biogen Inc. Has Something the Pharma Majors Want
Biogen Inc. (NASDAQ:BIIB) lost some 10% in one trading day last June. In fact, Biogen stock, dropped to its lowest price of the year, $224.60 on June 24. That happened as the company admitted that lab tests of its new multiple sclerosis (MS) targeting drug, Opicinumab, failed. But, such things happen in the world of biotech. In fact, Biogen stock has hit a new record high for 2016, gaining 10% in a single day as Merck & Co. (NYSE:MRK) and Allergan Plc. (NYSE:AGN) have shown takeover interest. That has sparked major.
Den vollständigen Artikel lesen ...
Biogen Inc. (NASDAQ:BIIB) lost some 10% in one trading day last June. In fact, Biogen stock, dropped to its lowest price of the year, $224.60 on June 24. That happened as the company admitted that lab tests of its new multiple sclerosis (MS) targeting drug, Opicinumab, failed. But, such things happen in the world of biotech. In fact, Biogen stock has hit a new record high for 2016, gaining 10% in a single day as Merck & Co. (NYSE:MRK) and Allergan Plc. (NYSE:AGN) have shown takeover interest. That has sparked major.
Den vollständigen Artikel lesen ...